

Jean-Michel Lavoie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/164863/publications.pdf>

Version: 2024-02-01

17
papers

377
citations

1163117

8
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

803
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.. Cold Spring Harbor Molecular Case Studies, 2022, 8, .	1.0	2
2	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. European Urology, 2021, 79, 16-19.	1.9	36
3	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	7.0	50
4	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. Oncologist, 2021, 26, e1381-e1394.	3.7	8
5	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. Urology Case Reports, 2021, 39, 101762.	0.3	0
6	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	12.8	85
7	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	1.9	30
8	Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. Canadian Urological Association Journal, 2020, 15, E123-E126.	0.6	0
9	Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis. Investigational New Drugs, 2020, 38, 1601-1604.	2.6	0
10	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer, 2020, 1, 452-468.	13.2	103
11	Current Management of Disseminated Germ Cell Tumors. Urologic Clinics of North America, 2019, 46, 377-388.	1.8	10
12	Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. Prostate, 2019, 79, 281-287.	2.3	15
13	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. Journal of Urology, 2019, 202, 49-56.	0.4	24
14	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 457-457.	1.6	3
15	Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).. Journal of Clinical Oncology, 2019, 37, 509-509.	1.6	2
16	18F FDG positron-emission tomography findings of gliomatosis peritonei: A case report and review of the literature. Gynecologic Oncology Reports, 2017, 20, 105-107.	0.6	9
17	The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. Blood, 2013, 122, 1804-1804.	1.4	0